Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 918 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Neoplasms Clear all
Terminated Phase 1 Interventional

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

NCT06336148
View directory record Official record
Conditions
Solid Tumor
Interventions
ACTM-838
Drug
Lead sponsor
Actym Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 26, 2026, 4:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Completed No phase listed Observational

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

NCT00671827
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Not applicable Interventional

Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears

NCT00483288
View directory record Official record
Conditions
Cervical Cancer
Interventions
educational intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 26, 2026, 4:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

NCT05438420
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Interventions
Q702, Pembrolizumab
Drug · Biological
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Completed No phase listed Observational

Sexual Functioning in Cervical Cancer Survivors

NCT00522223
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
folic acid, placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 26, 2026, 4:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496
View directory record Official record
Conditions
Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Gilbert, Arizona • Tucson, Arizona • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

NCT02725489
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Vigil, Durvalumab
Biological · Drug
Lead sponsor
Mary Crowley Medical Research Center
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 26, 2026, 4:36 AM EDT
Terminated Phase 1 Interventional

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

NCT04116320
View directory record Official record
Conditions
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions
Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
Device · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 26, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Ohio State University (OSU) SCREEN Community Program

NCT06666192
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
Interventions
Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
Other · Behavioral · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Phase 2 Interventional

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

NCT00257348
View directory record Official record
Conditions
Cervical Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 26, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

NCT00003525
View directory record Official record
Conditions
Cervical Cancer Stage IV, Vulvar Cancer, Stage IV
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 26, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Community Based Intervention to Improve Cervical Cancer Screening Among Women in the Hispanic and East African Immigrant Community

NCT07890402
View directory record Official record
Conditions
Cervical Carcinoma
Interventions
HPV Self-Collection, Informational Intervention, Interview, Survey Administration, Receive screening results, Receive recommended steps following abnormal results, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Active, not recruiting Not applicable Interventional

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

NCT06611553
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

NCT06492070
View directory record Official record
Conditions
Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Vulvar Carcinoma
Interventions
Best Practice, Cilostazol, Cryocompression Therapy, Paclitaxel, Quality-of-Life Assessment
Other · Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Terminated Phase 2 Interventional Results available

Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

NCT00138151
View directory record Official record
Conditions
Cervical Cancer
Interventions
recombinant interferon alpha-2b, isotretinoin, paclitaxel
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
6
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening

NCT02265120
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
20 Years to 70 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 26, 2026, 4:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT

NCT01372527
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Cervical Cancer
Interventions
TopCare: Use of provider knowledge vs. automated system
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
103,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 26, 2026, 4:36 AM EDT
Completed No phase listed Observational

Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

NCT00165126
View directory record Official record
Conditions
Endometrial Carcinoma, Cervix Cancer, Carcinoma of the Uterus
Interventions
Radiation therapy
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 26, 2026, 4:36 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Cervical Cancer Screening Through the Emergency Department - IIS

NCT06796738
View directory record Official record
Conditions
Cervical Cancers, HPV
Interventions
HPV testing
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121
View directory record Official record
Conditions
Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Interventions
ADRX-0706
Drug
Lead sponsor
Adcentrx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 26, 2026, 4:36 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

NCT05359016
View directory record Official record
Conditions
Cervical Cancer
Interventions
HPV testing of women for cervical cancer screening
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 49 Years · Female only
Enrollment
9,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 26, 2026, 4:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community Awareness, Resources and Education (CARE II): Project 3

NCT01299714
View directory record Official record
Conditions
Uterine Cervical Cancer
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
4
States / cities
Athens, Ohio • Gallipolis, Ohio • Logan, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 26, 2026, 4:36 AM EDT